Qualigen Therapeutics Announces Pre-IND Feedback from U.S. Food and Drug Administration Regarding QN-302 for the Treatment of G4-Targeted Advanced Solid Tumors
Stock Information for Qualigen Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.